The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool. (2019)
Attributed to:
MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.breast.2019.01.005
PubMed Identifier: 30703670
Publication URI: http://europepmc.org/abstract/MED/30703670
Type: Journal Article/Review
Volume: 44
Parent Publication: Breast (Edinburgh, Scotland)
ISSN: 0960-9776